Alison Moore Biography and Net Worth

President and CEO of Codexis

Alison Moore was named President and CEO of Codexis in November 2025 after having served as Chief Technical Officer since September 2024 and as a director from 2020 to 2024. Dr. Moore brings to Codexis significant experience as a biotechnology and pharmaceutical executive, including an extensive background in biomanufacturing. She is former Chief Technical Officer of Allogene Therapeutics, a pioneering clinical-stage, biotechnology company advancing CAR-T therapies. Prior to Allogene she spent a total of 20 years at Amgen, most recently as Senior Vice President, Process Development, including roles in Supply Chain and Manufacturing. Dr. Moore also has experience at Genentech as a Director in Chemistry, Manufacturing and Controls, and Regulatory Affairs. Dr. Moore holds a bachelor’s degree in Pharmacology with Honors and a PhD in Cell Biology from Manchester University, England.

What is Alison Moore's net worth?: The estimated net worth of Alison Moore is at least $553.62 thousand as of February 6th, 2026. Dr. Moore owns 250,506 shares of Codexis stock worth more than $553,618 as of July 20th. This net worth estimate does not reflect any other assets that Dr. Moore may own. Learn More about Alison Moore's net worth.
How do I contact Alison Moore?: The corporate mailing address for Dr. Moore and other Codexis executives is 200 PENOBSCOT DRIVE, REDWOOD CITY CA, 94063. Codexis can also be reached via phone at (650) 421-8100 and via email at [email protected]. Learn More on Alison Moore's contact information.
Has Alison Moore been buying or selling shares of Codexis?: Alison Moore has not been actively trading shares of Codexis during the past quarter. Most recently, Alison Moore sold 3,826 shares of the business's stock in a transaction on Friday, February 6th. The shares were sold at an average price of $1.31, for a transaction totalling $5,012.06. Following the completion of the sale, the chief executive officer now directly owns 250,506 shares of the company's stock, valued at $328,162.86. Learn More on Alison Moore's trading history.
Who are Codexis' active insiders?: Codexis' insider roster includes Raymond De Vré (Director), Byron Dorgan (Director), Georgia Erbez (Chief Financial Officer and Chief Business Officer), Bernard Kelley (Director), Stefan Lutz (Chief Scientific Officer), Alison Moore (President and CEO), John Nicols (CEO), Kevin Norrett (COO), Dennis Wolf (Director), and Patrick Yang (Director). Learn More on Codexis' active insiders.
Are insiders buying or selling shares of Codexis?: In the last year, insiders at the biotechnology company sold shares 8 times. They sold a total of 35,774 shares worth more than $65,308.44. The most recent insider tranaction occured on June, 11th when Director Vre Raymond De sold 2,605 shares worth more than $6,173.85. Insiders at Codexis own 3.5% of the company. Learn More about insider trades at Codexis.
Information on this page was last updated on 6/11/2026.

Alison Moore Insider Trading History at Codexis

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
2/6/2026	Sell	3,826	$1.31	$5,012.06	250,506
10/13/2025	Sell	6,239	$2.51	$15,659.89	169,332

Alison Moore Buying and Selling Activity at Codexis

Codexis Company Overview

Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.

Today's Range

Now: $2.21

$2.14

$2.27

50 Day Range

MA: $2.48

$2.13

$2.80

2 Week Range

Now: $2.21

$0.96

$3.87

Volume

506,418 shs

Average Volume

812,612 shs

Market Capitalization

$200.89 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.5